Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.40 |
| ▸ | RET | P07949 | 5/20 | 0.40 |
| ▸ | PIM1 | P11309 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 5/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.40 |
| ▸ | PLK4 | O00444 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | PRKCG | P05129 | 4/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.40 |
| ▸ | NEK4 | P51957 | 4/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 4/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.40 |
| ▸ | LCK | P06239 | 4/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711 | 0.91 | PLK4 (0.32) | MAP4K4RETPIM1FLT3MAP4K2 | |
| SCHEMBL17354222 | 0.90 | MAPT (0.39) | MAP4K4RETPIM1FLT3MAP4K2 | |
| SCHEMBL14850224 | 0.88 | RET (0.32) | MAP4K4RETPIM1FLT3MAP4K2 | |
| SCHEMBL17354233 | 0.88 | S1PR1 (0.33) | MAP4K4RETPIM1FLT3MAP4K2 | |
| SCHEMBL14850228 | 0.86 | MAPT (0.42) | NPC1SMN1; SMN2GAAKDM4ERAB9A | |
| SCHEMBL14850256 | 0.86 | MAP4K4 (0.41) | MAP4K4RETPIM1FLT3MAP4K2 | |
| SCHEMBL14853447 | 0.83 | BDKRB1 (0.41) | MAP4K4PIM1FLT3MAP4K2ROCK1 | |
| SCHEMBL14029 | 0.83 | DYRK3 (0.31) | MAP4K4RETFLT3ROCK1AURKB | |
| SCHEMBL17354220 | 0.83 | DYRK3 (0.35) | MAP4K4RETFLT3ROCK1AURKB | |
| SCHEMBL14141 | 0.82 | RAB9A (0.35) | PIM1ROCK1CDK2PIM3SLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | MAP4K4 3931/4885RET 4806/4885PIM1 1749/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | MAP4K4 3931/4885RET 4806/4885PIM1 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.